Tirzepatide (sold as Mounjaro for type 2 diabetes and Zepbound for weight management) is a dual GIP and GLP-1 receptor agonist administered via weekly injection. It provides major clinical benefits, including substantial weight loss of up to 20% or more, effective blood sugar reduction and HbA1c control, lowered cardiovascular and stroke risks, and relief from obstructive sleep apnea. 

Weight Loss & Appetite

• Significant fat reduction: Clinical trials show average body weight drops between 15% and 20.9%.

• Appetite suppression: Targets brain receptors to lower hunger signals and intense food cravings.

• Delayed gastric emptying: Keeps food in the stomach longer to extend the feeling of fullness after eating. 

Blood Sugar & Metabolic Health

• Glycemic control: Stimulates insulin secretion conditionally and lowers glucagon production to stabilize blood sugar.

• Improved insulin sensitivity: Enhances how the body responds to its own insulin, reducing overall hyperinsulinemia. 

Cardiovascular & Systemic Effects

• Heart protection: Lowers risks of major adverse cardiac events, heart attacks, and strokes.

• Blood pressure support: Helps lower resting blood pressure and improves overall lipid profiles.

• Reduced inflammation: Decreases systemic inflammatory markers associated with metabolic dysfunction.